Compare Stocks: GPCR, ELAN, AXSM, and ARWR

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARWR Arrowhead Pharmaceuticals	$85.31 -2.3%	$78.84	$15.01 ▼ $95.49	$12.02B	1.26	2.47 million shs	587,597 shs
AXSM Axsome Therapeutics	$219.41 -6.5%	$239.57	$96.09 ▼ $260.19	$11.25B	0.6	765,393 shs	347,489 shs
ELAN Elanco Animal Health	$26.22 -0.9%	$24.45	$13.39 ▼ $27.72	$13.09B	1.68	5.29 million shs	1.87 million shs
GPCR Structure Therapeutics	$47.14 -4.7%	$46.33	$15.80 ▼ $94.90	$3.34B	-1.5	905,004 shs	112,950 shs

7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARWR Arrowhead Pharmaceuticals	+1.28%	+0.62%	+7.13%	+18.84%	+456.18%
AXSM Axsome Therapeutics	+3.17%	-2.85%	-4.14%	+12.94%	+131.72%
ELAN Elanco Animal Health	+0.49%	+6.86%	+7.48%	+18.35%	+87.54%
GPCR Structure Therapeutics	+4.48%	-2.62%	-7.83%	+19.35%	+177.45%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARWR Arrowhead Pharmaceuticals	$85.31 -2.3%	$78.84	$15.01 ▼ $95.49	$12.02B	1.26	2.47 million shs	587,597 shs
AXSM Axsome Therapeutics	$219.41 -6.5%	$239.57	$96.09 ▼ $260.19	$11.25B	0.6	765,393 shs	347,489 shs
ELAN Elanco Animal Health	$26.22 -0.9%	$24.45	$13.39 ▼ $27.72	$13.09B	1.68	5.29 million shs	1.87 million shs
GPCR Structure Therapeutics	$47.14 -4.7%	$46.33	$15.80 ▼ $94.90	$3.34B	-1.5	905,004 shs	112,950 shs

7 Stocks That Could Lead the Next Market Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARWR Arrowhead Pharmaceuticals	+1.28%	+0.62%	+7.13%	+18.84%	+456.18%
AXSM Axsome Therapeutics	+3.17%	-2.85%	-4.14%	+12.94%	+131.72%
ELAN Elanco Animal Health	+0.49%	+6.86%	+7.48%	+18.35%	+87.54%
GPCR Structure Therapeutics	+4.48%	-2.62%	-7.83%	+19.35%	+177.45%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARWR Arrowhead Pharmaceuticals	2.62	Moderate Buy	$96.92	13.61% Upside
AXSM Axsome Therapeutics	2.91	Moderate Buy	$261.48	19.17% Upside
ELAN Elanco Animal Health	2.77	Moderate Buy	$28.73	9.58% Upside
GPCR Structure Therapeutics	2.89	Moderate Buy	$110.55	134.50% Upside

Current Analyst Ratings Breakdown

Latest GPCR, ELAN, AXSM, and ARWR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/30/2026	ARWR Arrowhead Pharmaceuticals	B. Riley Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$101.00 ➝ $123.00
7/27/2026	ARWR Arrowhead Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$100.00 ➝ $115.00
7/23/2026	ARWR Arrowhead Pharmaceuticals	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$100.00 ➝ $120.00
7/23/2026	ARWR Arrowhead Pharmaceuticals	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight	$110.00 ➝ $126.00
7/22/2026	ARWR Arrowhead Pharmaceuticals	Chardan Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$90.00 ➝ $115.00
7/22/2026	ELAN Elanco Animal Health	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Equal Weight	$23.00 ➝ $26.00
7/20/2026	AXSM Axsome Therapeutics	BMO Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$310.00
7/20/2026	AXSM Axsome Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold ➝ Strong Sell
7/20/2026	AXSM Axsome Therapeutics	BMO Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
7/17/2026	AXSM Axsome Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/17/2026	GPCR Structure Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)

(Data available from 7/31/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARWR Arrowhead Pharmaceuticals	$829.45M	14.49	$0.12 per share	722.11	$3.64 per share	23.44
AXSM Axsome Therapeutics	$638.50M	17.68	N/A	N/A	$1.75 per share	125.38
ELAN Elanco Animal Health	$4.89B	2.68	$2.31 per share	11.37	$13.18 per share	1.99
GPCR Structure Therapeutics	N/A	N/A	N/A	N/A	$24.99 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARWR Arrowhead Pharmaceuticals	-$1.63M	-$2.15	N/A	N/A	N/A	-48.38%	-55.09%	-18.13%	8/4/2026 (Estimated)
AXSM Axsome Therapeutics	-$183.17M	-$3.73	N/A	54.04	N/A	-26.59%	-267.16%	-28.53%	8/10/2026 (Estimated)
ELAN Elanco Animal Health	-$232M	-$0.50	N/A	21.14	1.72	-4.95%	7.42%	3.66%	8/5/2026 (Estimated)
GPCR Structure Therapeutics	-$141.20M	-$0.87	N/A	N/A	N/A	N/A	-24.91%	-23.67%	8/6/2026 (Estimated)

Latest GPCR, ELAN, AXSM, and ARWR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/10/2026	Q2 2026	AXSM Axsome Therapeutics	-$0.8913	N/A	N/A	N/A	$220.92 million	N/A
8/6/2026	Q2 2026	GPCR Structure Therapeutics	-$0.39	N/A	N/A	N/A	N/A	N/A
8/5/2026	Q2 2026	ELAN Elanco Animal Health	$0.28	N/A	N/A	N/A	$1.31 billion	N/A
8/4/2026	Q3 2026	ARWR Arrowhead Pharmaceuticals	-$1.2767	N/A	N/A	N/A	$44.17 million	N/A
5/7/2026	Q2 2026	ARWR Arrowhead Pharmaceuticals	-$1.0950	-$0.93	+$0.1650	-$0.93	$73.84 million	$73.74 million
5/7/2026	Q1 2026	GPCR Structure Therapeutics	-$0.39	-$0.35	+$0.04	-$0.35	$11.11 million	N/A
5/6/2026	Q1 2026	ELAN Elanco Animal Health	$0.34	$0.40	+$0.06	$0.11	$1.28 billion	$1.37 billion
5/4/2026	Q1 2026	AXSM Axsome Therapeutics	-$0.85	-$1.26	-$0.41	-$1.26	$191.10 million	$191.20 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARWR Arrowhead Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
AXSM Axsome Therapeutics	N/A	N/A	N/A	N/A	N/A
ELAN Elanco Animal Health	N/A	N/A	N/A	N/A	N/A
GPCR Structure Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARWR Arrowhead Pharmaceuticals	1.41	6.23	6.23
AXSM Axsome Therapeutics	2.27	1.39	1.32
ELAN Elanco Animal Health	0.60	2.16	1.12
GPCR Structure Therapeutics	N/A	26.16	26.16

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARWR Arrowhead Pharmaceuticals	62.61%
AXSM Axsome Therapeutics	81.49%
ELAN Elanco Animal Health	97.48%
GPCR Structure Therapeutics	91.78%

Insider Ownership

Company	Insider Ownership
ARWR Arrowhead Pharmaceuticals	3.60%
AXSM Axsome Therapeutics	20.60%
ELAN Elanco Animal Health	1.14%
GPCR Structure Therapeutics	5.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARWR Arrowhead Pharmaceuticals	400	140.86 million	135.79 million	Optionable
AXSM Axsome Therapeutics	380	51.46 million	40.86 million	Optionable
ELAN Elanco Animal Health	9,400	499.45 million	493.76 million	Optionable
GPCR Structure Therapeutics	136	71.07 million	67.17 million	Optionable

GPCR, ELAN, AXSM, and ARWR Headlines

Recent News About These Companies

Janus Henderson Group PLC Purchases 264,833 Shares of Structure Therapeutics Inc. Sponsored ADR $GPCR

July 31 at 5:51 AM | marketbeat.com

Structure Therapeutics (GPCR) Projected to Release Quarterly Earnings on Thursday

July 30 at 6:40 AM | marketbeat.com

Stempoint Capital LP Cuts Position in Structure Therapeutics Inc. Sponsored ADR $GPCR

July 30 at 6:07 AM | marketbeat.com

Rock Springs Capital Management LP Sells 108,019 Shares of Structure Therapeutics Inc. Sponsored ADR $GPCR

July 28 at 6:56 AM | marketbeat.com

Structure Therapeutics Inc. Sponsored ADR $GPCR Shares Bought by Orbimed Advisors LLC

July 27, 2026 | marketbeat.com

A small-cap contender looking to challenge the weight-loss drug giants

July 24, 2026 | msn.com

PSquared Asset Management AG Buys Shares of 35,000 Structure Therapeutics Inc. Sponsored ADR $GPCR

July 24, 2026 | marketbeat.com

Siren L.L.C. Acquires 250,000 Shares of Structure Therapeutics Inc. Sponsored ADR $GPCR

July 24, 2026 | marketbeat.com

Structure Therapeutics Inc. Sponsored ADR $GPCR Stake Lessened by Monashee Investment Management LLC

July 23, 2026 | marketbeat.com

SEB Asset Management AB Purchases New Shares in Structure Therapeutics Inc. Sponsored ADR $GPCR

July 21, 2026 | marketbeat.com

Financial Review: IN8bio (NASDAQ:INAB) and Structure Therapeutics (NASDAQ:GPCR)

July 20, 2026 | americanbankingnews.com

Comparing Dermata Therapeutics (NASDAQ:DRMA) & Structure Therapeutics (NASDAQ:GPCR)

July 20, 2026 | americanbankingnews.com

Structure Therapeutics (NASDAQ:GPCR) Trading 4.8% Higher - Here's Why

July 17, 2026 | marketbeat.com

Principal Financial Group Inc. Grows Stock Position in Structure Therapeutics Inc. Sponsored ADR $GPCR

July 17, 2026 | marketbeat.com

Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) Receives Average Recommendation of "Moderate Buy" from Brokerages

July 13, 2026 | marketbeat.com

Structure Therapeutics (GPCR) Is A Hidden Biotech Multibagger Stock To Buy Now

July 3, 2026 | finance.yahoo.com

H.C. Wainwright Reiterates Buy Rating for Structure Therapeutics (GPCR)

June 17, 2026 | finance.yahoo.com

Why The Small-Cap Drug Story Quietly Drawing Attention?

June 16, 2026 | kalkinemedia.comK

Structure Therapeutics: My Top Small-Cap Pick For The Obesity Market (Upgrade)

June 11, 2026 | seekingalpha.com

Analysts Offer Insights on Healthcare Companies: Alkermes (ALKS) and Structure Therapeutics, Inc. Sponsored ADR (GPCR)

June 9, 2026 | theglobeandmail.com

Structure Therapeutics Inc. (GPCR) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

June 9, 2026 | seekingalpha.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

GPCR, ELAN, AXSM, and ARWR Company Descriptions

Arrowhead Pharmaceuticals NASDAQ:ARWR

$85.31 -2.01 (-2.30%)

As of 12:53 PM Eastern

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases. In addition, the company is involved in the development of JNJ-3989, which is in Phase 2 clinical trial to treat chronic hepatitis B virus infection; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; GSK-4532990 that is in phase 2 clinical trial to treat liver diseases; HZN-457, which is in phase 1 clinical trial to treat uncontrolled gout; and Fazirsiran that is in Phase 3 clinical trial for the treatment for liver disease associated with alpha-1 antitrypsin deficiency. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreements with Janssen Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Horizon Therapeutics Ireland DAC; Amgen Inc.; and Glaxosmithkline Intellectual Property (No. 3) Limited. The company was founded in 2003 and is headquartered in Pasadena, California.

Axsome Therapeutics NASDAQ:AXSM

$219.41 -15.23 (-6.49%)

As of 12:53 PM Eastern

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.

Elanco Animal Health NYSE:ELAN

$26.22 -0.25 (-0.93%)

As of 12:53 PM Eastern

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands. The company sells its products to third-party distributors; veterinarians; and farm animal producers, including beef and dairy farmers, as well as pork, poultry, and aquaculture operations. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Greenfield, Indiana.

Structure Therapeutics NASDAQ:GPCR

$47.14 -2.33 (-4.71%)

As of 12:53 PM Eastern

Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. It is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073, a biased agonist for apelin receptor, a GPCR that has been implicated in idiopathic pulmonary fibrosis (IPF); and LTSE-2578, an investigational oral small molecule lysophosphatidic acid 1 receptor antagonist for the treatment of IPF and PPF. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest GPCR, ELAN, AXSM, and ARWR Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest GPCR, ELAN, AXSM, and ARWR Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

GPCR, ELAN, AXSM, and ARWR Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

GPCR, ELAN, AXSM, and ARWR Company Descriptions

Arrowhead Pharmaceuticals NASDAQ:ARWR

Axsome Therapeutics NASDAQ:AXSM

Elanco Animal Health NYSE:ELAN

Structure Therapeutics NASDAQ:GPCR

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest GPCR, ELAN, AXSM, and ARWR Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest GPCR, ELAN, AXSM, and ARWR Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

GPCR, ELAN, AXSM, and ARWR Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

GPCR, ELAN, AXSM, and ARWR Company Descriptions

Arrowhead Pharmaceuticals NASDAQ:ARWR

Axsome Therapeutics NASDAQ:AXSM

Elanco Animal Health NYSE:ELAN

Structure Therapeutics NASDAQ:GPCR

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools